Positive Asian Results Set Stage For Japan Perampanel Filing
This article was originally published in PharmAsia News
Eisai has unveiled additional positive results for its novel anti-epileptic drug perampanel, this time from an Asian trial in refractory patients that will be used to support a planned Japanese approval filing.
You may also be interested in...
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.